Expression of negative immune checkpoints TIM-3 and FCRL-3 on Tregs not only distinguish healthy controls from RA and SLE patients but can be used to differentiate between different rheumatic diseases. These findings indicate that Tregs trigger the regulation of the immune response in RA and SLE, yet the activation of different Treg subsets is disease-specific.
metabolic drivers of Th17 pathogenicity. COMPASS pointed to the known association of the glycolytic pathway with Th17 activation, and further revealed novel metabolic targets, which were seldom studied in relation to autoimmunity and Th17 pathogenicity. Results: To validate the findings of COMPASS we performed targeted metabolomics as well as carbon-tracing experiments thereby showing differential use of these pathways by non-pathogenic and pathogenic Th17 cells respectively. Interference in these pathways in Th17 cells, using genetic deletion and small molecular weight inhibitors of metabolic targets, resulted in alteration in cell pathogenicity in cell culture experiments in vitro and in an autoimmune disease model in vivo. In order to explore potential mechanisms for the observed effects we performed RNA-seq as well as ATACseq and noted distinct alterations in the Th17 program of the targeted cells. Conclusion: Overall, this study establishes a central role of these newly identified pathways in regulating pathogenicity of Th17 cells. Aim: Rituximab (RTX) is a monoclonal antibody that targets the CD20 surface marker. This results in a reduction of CD20+ immune cell populations, foremost B cells. B cell depletion via RTX was found to be beneficial for patients suffering from systemic sclerosis (SSc), leading to an improvement of skin fibrosis and autoimmunity. However, little is known about the influence of RTX on specific B subsets in SSc. The purpose of this study was to further characterize the effect of RTX on B cell populations in patients with SSc.
Rituximab treatment significantly reduces circulating CD86+ b cells in systemic sclerosis
Abstracts found to negatively impact osteogenesis and bone regeneration in vitro, by controlling the differentiation of mesenchymal stem cells. But to date the role of miR-146a in bone remodelling, its influence on bone stability and development of osteoporosis is not known. Methods: Systemic bone, tibiae and femur, of wt, miR-146a-/-and miR-146a-/-TRAF6+/− animals was assessed histologically and via µCT analysis, over a period of 3 to 18 months of age. Serum cytokine levels were analysed by Elisa. Expression levels of MRNA in bone were analysed by qPCR. To induce osteoporosis, ovariectomy (OVX) induced bone loss was performed. Results: When we analysed bone volume of long bones histologically as well as with µCT analysis we detected significantly increased trabecular as well as cortical bone mass in miR-146a deficient compared to wt animals, starting at an age of 6 months. Dose reduction of TRAF6, a main target of miR-146a, using miR-146a−/− TRAF6+/− animals could not change the observed bone phenotype. Analysis of serum in aged miR-146a deficient animals displayed elevated activity of bone resorbing osteoclasts as amounts of CTX I in miR-146a−/− mice were significantly increased compared to wt animals. Q-PCR analysis of important osteoclast as well as osteoblast marker genes in bones ex vivo displayed elevated expression of signature molecules of both cell types in aged miR-146a deficient mice, suggesting a regulatory role of miR-146a in both cell types. Moreover, expression level of Wnt5a, a known target of miR-146a, influencing bone forming as well as bone resorbing cells, was strongly elevated in miR-146a−/− bones, possibly responsible for this deregulated bone growth. When we induced osteoporosis using the OVX disease model, histological analysis of long bones showed significant trabecular bone loss in ovariectomized wt mice. In contrast, we could not detect trabecular bone loss in ovariectomized miR-146a knock out animals, suggesting that loss of miR-146a deficiency protects bone loss induced by estrogen deficiency. Conclusion: MiR-146a seems to control bone turnover and miR-146a deficient mice accrue bone over time. Moreover this miRNA has a negative influence on bone loss occurring during oestrogen loss induced osteoporosis. Therefore miR-146a could be possibly used as a therapeutic target in the treatment of osteoporosis.
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Lymphopenia in primary Sjögren's Syndrome is associated with premature aging of naïve CD4+ T-cells 1.7 STAT signaling profiles in peripheral leucoyctes stratify patients with rheumatoid arthritis B. Dreo, R. Husic, P. Bosch, A. Lackner, W. Graninger, J. Fessler, H. Brezinsek, M. Stradner Klinische Abteilung für Rheumatologie und Immunologie, Graz, Austria Aim: In rheumatoid arthritis (RA) stratification is considered an important step towards the development of patient-tailored therapeutic concepts. The fact that less than 50 % of RA patients experience a substantial improvement in response to any single biologic therapy has brought up the idea that yet unidentified subtypes of RA (endotypes) might exist. This concept is in line with distinct microscopic patterns of synovitis found in biopsies of RA joints. Furthermore, a subset of RA patients has leucocytes with interferon driven gene expression, whereas the majority of RA patients does not. Interferons activate receptor associated Janus kinases leading to phosphorylation of STAT1 and STAT2. Other STAT family members are activated by cytokines such as IL-6 (STAT3) or IL-15 (STAT5). Therefore, the phosphorylation pattern of the different STAT molecules in circulating leucocytes might mirror the specific cytokine milieu of a given patient. Our objective for this study was to define endotypes of RA based on the phosphorylation patterns of the different STAT molecules in circulating leucocytes. Methods: Cross-sectional study of 63 patients with established RA fulfilling the 2010 EULAR/ACR criteria (mean age: 64.5 ± 1.7 (SEM) years, female ratio: 0.79). Nine healthy subjects served as a control group. Flow cytometry was performed to detect the phosphorylated forms of STAT1-6 in Monocytes, Granulocytes, B cells, naïve-, effector-, and memory-T cells of the CD4+ and CD4-lineage. All steps from blood draw to cell fixation were performed at 4 °C to prevent auto-activation of leucocytes. The mean fluorescence intensity (MFI) of fluorochrome labeled antibodies against phosphorylated STATs in the different leucocyte populations was used for statistical analysis. MFIs were correlated with disease activity measured by the cDAI. MFIs of populations with elevated STAT phosphorylation not associated with disease activity were analyzed by unsupervised hierarchical clustering. The resulting groups were validated by principal component analysis. Finally, criteria for patient assignment to specific groups by MFI were generated by calculating ROC-curves. Results: Pronounced ex vivo phosphorylation of STAT1-6 in any leucocyte population was detected in 30 of 63 (48 %) RA patients but not in healthy subjects (n=10). Active STAT5 signaling in Monocytes, naïve CD4+ T cells and CD4+ effector T cells was significantly associated with disease activity. Unsupervised hierarchical cluster analysis of RA patients based on pSTAT MFIs not associated with disease activity resulted in 3 groups: 1) Patients with active STAT1 and STAT3 signal in Monocytes and Granulocytes (n=14/63, 22 %) , 2) Patients with active STAT5 signal in naïve CD8+ T cells, CD8+ effector T cells and CD4+ memory T cells (n=16/63, 25 %) and 3) Patients without active STAT signal in any leucocyte population (n=33/63, 52 %). cDAI, CRP, ESR, current treatment, RF and ACPA status did not differ significantly between the groups. To test if the assignment to a group changed over time, we performed a second analysis of STAT phosphorylation after 3-6 months. Seventy percent of the patients tested (11/16) were re-assignment to their initial group. Conclusion: We identified three distinct RA endotypes based on active STAT signal. Whether patients within different endotypes respond differently to a given therapy will be subject to further research.
RA. The expression of their key transcription factors is controlled by histone modifications which includes acetylation of lysine residues mediated by histone deacetylases (HDAC). Indeed, pan HDAC inhibitors have been shown to be a potential therapeutic strategy. However, major side effects limited the clinical use and underline the need of more specific HDAC inhibitors. We therefore addressed the individual role of HDAC1 on the development of collagen-induced arthritis model (CIA). Methods: Mice with a T cell specific deletion of HDAC1 (HDAC1 cKO) were generated by using the CD4Cre/LoxP system. Collagen induced arthritis (CIA) was induced at week 8. Animals were scored for paw swelling and grip strength. After 10 weeks, mice were sacrificed and paraffin sections of the affected joints were analysed for histomorphologic signs of inflammation, cartilage and bone destruction. Anti-CII antibody levels were determined by ELISA. Serum samples were analysed for various cytokines by multiplex assays. CCR6 expression in CD4 T cells was analysed by flow cytometry. Results: To address potential effects of HDAC1 in the pathogenesis of RA, CIA was induced in HDAC1cKO mice and WT mice. Surprisingly HDAC1cKO mice were completely protected from the development of arthritis. In line with the clinical data, histological analysis revealed no signs of inflammation, no bone erosion and no osteoclasts in the joints of HDAC1cKO mice. Anti-CII antibodies, including total IgG and igG2c were detected in HDAC1cKO and WT mice. Surprisingly, IL-17 was significantly decreased in the serum of HDAC1 cKO mice as compared to WT mice, suggesting a role of HDAC1 in the development of Th17 cells. To see whether HDAC1 is involved in the regulation of the chemokine receptor 6 (CCR6), the main marker of Th17 cells, we compared the upregulation of CCR6 in CD4+ T cells from WT and HDAC1cKO mice. Indeed, CCR6 could not be upregulated in CD4+ T cells from HDAC1cKO mice upon IL-6 in vitro. These data support the role of HDAC1 in the regulation of CCR6, an important chemokine receptor, which is necessary for the migration of pathogenic Th17 cells and therefore for the development of arthritis. Conclusion: Our data show the importance of HDAC1 as a key immune regulator in the pathogenesis of T cell driven collagen induced arthritis. Therefore, it might be considered as an interesting novel therapeutic target in RA. Aim: Vaginal infections are a risk factor for preterm delivery. In this study, we sought to evaluate the vaginal flora of pregnant women who suffer from inflammatory rheumatic disease (IRD) and inflammatory bowel disease (IBD) in comparison to control women without these autoimmune conditions. Methods: We collected the data from a total of 7748 women with singleton pregnancies who underwent routine screening for asymptomatic vaginal infections between 10 + 0 and 16 + 0 gestational weeks. Vaginal smears were Gram-stained, and microscopically evaluated for bacterial vaginosis, candidiasis, and trichomoniasis. In a retrospective manner, data of 195 women with inflammatory rheumatic or inflammatory bowel disease Conclusion: In pSS extensive proliferation of naïve CD4+ T-cells earlier in life is associated with a senescent phenotype unable to sustain homeostasis. The resulting lack of naïve CD4+ T-cells forms the basis of lymphopenia frequently observed in pSS. Aim: Rheumatoid arthritis (RA) is a chronic debilitating autoimmune disease, which affects 1 % of the population and is characterized by synovial inflammation. The RA synovial tissue is composed of a variety of cell types, including fibroblast-like synoviocytes (FLS) and T-cells. Although previous publications point to a role of T-cell-FLS interactions, the main mechanism and the contribution to disease development and progression remains unknown. We therefore aimed to establish an experimental system, which allows studying T-cell-FLS interactions. Methods: RA patient derived FLS were isolated from synovial tissue that was acquired during synovectomy. Using fluorescence activated cell sorting (FACS) of patient-derived PBMCs, naïve CD4+ T-cells were gathered to establish a co-culture that allows for examining consequences of Tcell-FLS interactions. By adding different pro-inflammatory cytokines, this system allows for deciphering the effects of the inflammatory synovial environment on T-cell-FLS interaction using automated fluorescence microscopy and downstream bioinformatic image analysis. Furthermore, by re-isolation of T-cells from co-culture, effects on T-cell activation and differentiation can be investigated using flow cytometry. Results: We successfully established a co-culture system to visualize and quantify T-cell-FLS interactions. Our data confirmed enhanced T-cell-FLS interactions, in particular when T-cells were activated using CD3/ CD28 stimulation. Re-isolated T-cells from co-culture showed increased upregulation of early and late T-cell activation markers especially after pretreatment of FLS with IFN-γ. Conclusion: In conclusion, our data show that FLS interact with T-cells, which as a consequence leads to enhanced T cell activation. These data highlight a potential role of T-cell-FLS interactions as a major driver of local inflammation. A further understanding of T-cell-FLS interactions will help to develop new therapeutic strategies for the treatment of RA patients. [91 %; OR 0.49 (95 % CI, ; p < 0.001]. Candidiasis occurred more frequently in pregnant women with inflammatory rheumatic and bowel disease than in controls [OR 2.11 (95 % CI, ; p < 0.001]. Findings were inconclusive regarding bacterial vaginosis (± candidiasis) and trichomoniasis. The newborn of women with IRD and IBD had a lower mean birth weight [MD − 165.3 g (95 % CI, −283.6 to −46.9); p =0.006] compared to infants of the control group. Conclusion: Pregnant women with systemic autoimmune inflammatory conditions are at risk for asymptomatic vaginal infections. As recurrent candidiasis is associated with preterm delivery, the vulnerability of this patient population should lead to consequent antenatal infection screening and therapy at early gestation. Aim: The aim of this prospective study was to examine whether ultrasound or clinical abnormalities at enthesal sites predict radiographic progression at entheses in Psoriatic Arthritis (PsA). Methods: Consecutive PsA patients were included and subjected to clinical and ultrasound assessments at 14 entheses at baseline, 6 and 12 months. Radiographs were performed at 0 and 12 months. By US, we investigated structural (erosions, osteophytes) and inflammatory changes (grey scale (0-32) and Power Doppler (0-14, range global ultrasound score 0-140), and radiographs were evaluated for enthesophytes and erosions (score range 0-56). Multivariate regression models were conducted to identify the possible association of clinical and ultrasound findings with radiographic progression. Results: We examined 83 patients at baseline, of whom 43 (51.8 %) had complete clinical, ultrasound and x-ray data. Twenty-four of 43 patients (55.8 %) developed radiographic progression of entheses. These patients were younger (49.6 vs. 59.3, p=0.005), had shorter disease duration (9.7 vs. 17.9 years, p=0.015) and lower clinical disease activity at 6-months (DAP-SA 6.7 vs. 17.0, p=0.018) as compared to patients without progression. Non-progressors had higher ultrasound enthesiophyte scores at baseline than progressors (20 vs. 15, p<0.05) . The multivariate regression analysis revealed that 48.6 % of the variance of the x-ray score at 12-months FU (RegcoeffB=0.827, p=0.000) could be explained by the baseline US enthesiophyte score. Conclusion: Our data indicate that radiographic progression at entheses is linked with age, disease duration and ultrasound verified enthesophytes at baseline. No other ultrasound parameter predicted radiographic progression at entheses. manifestations. Ixekizumab (IXE) is approved for the treatment of moderate to severe psoriasis and more recently for active PsA. This post-hoc analysis describes the efficacy of IXE at week 24 in different phenotypes of PsA patients. Methods: Biologic naïve patients (SPIRIT-P1) were randomized to IXE 80 mg (initial dose 160 mg) every 4 (Q4W; N=107) or 2 weeks (Q2W; N=103), to adalimumab 40 mg (Q2W; N=101), or to placebo (PBO; N=106). Patients who had an inadequate response or intolerance to TNF inhibitors (SPIRIT-P2) were randomized to IXE Q4W (N=122) or Q2W (N=123), or to PBO (N=118). Patients fulfilled the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria and had active disease with ≥3TSJ and 3≥SJC. Patients were classified according to the following phenotypes of PsA: polyarthritis (≥5TJC and/or ≥5SJC), oligoarthritis (<5TJC and <5SJC), DIP joint only, enthesitis and dactylitis according to either the investigator's judgment or a scale-based definition. In each phenotype ACR 20, 50 and 70 response criteria, Minimal Disease Activity Psoriasis Area Severity Index (MDAPASI), and Disease Activity Psoriatic Arthritis (DAPSA) remission and low disease activity (LDA) response criteria were assessed to evaluate IXE effect at week 24 combining both doses. For each phenotype with a sufficient sample size, the IXE-and PBOtreated patients' baseline characteristics were assessed. Treatment effects of IXE and PBO were compared using Chi-square tests (or Fisher's exact tests if appropriate) within each phenotype. Results: The most frequent phenotypes were polyarthritis (N=662), enthesitis (investigator: N=459; LEI>0: N=403), and dactylitis (investigator: N=220; LDI-B>0: N=155). Too small sample sizes due to inclusion criteria or low frequency were observed for "DIP joint only", oligoarthritis and arthritis mutilans phenotypes (N=22, N=17 and N= 15; respectively). Baseline patient characteristics were generally balanced between treatment arms and similar between the 3 most frequent phenotypes, with no difference in disease activity and duration. Efficacy of IXE was consistent across the different phenotypes for various outcomes at week 24: ACR20/50/70, MDAPASI, DAPSA remission and DAPSA-LDA in SPIRIT trials irrespective of previous biologic DMARD use (. Tab. 1). Response rates were consistent to overall efficacy reported with IXE in SPIRIT trials. Conclusion: Treatment responses with IXE at week 24 were consistent regardless of the phenotypes. Aim: COAST-V (NCT02696785) is the first Phase 3 study of ixekizumab (IXE), a high-affinity anti-IL-17A monoclonal antibody, in patients with active radiographic axial spondyloarthritis (r-axSpA) who are biologic DMARD (bDMARD) naive. We report the Week (Wk) 16 primary endpoint and key efficacy and safety data from this ongoing 52-wk study. Methods: Adults with active r-axSpA per Assessment of SpA international Society (ASAS) criteria (sacroiliitis centrally defined by modified New York Criteria and ≥1 SpA feature), BASDAI ≥4, back pain ≥4 and inadequate response or intolerance to NSAID therapy, were randomized 1:1:1:1 to subcutaneous placebo (PBO), 80 mg IXE every 4 (Q4W) or 2 (Q2W) wks, with either 80-mg or 160-mg starting dose (assigned 1:1), or 40 mg adalimumab (ADA) Q2W (active reference arm) up to Wk 16. The primary endpoint was ASAS40 response at Wk 16. Major secondary endpoints included: ASAS20, BASDAI50 and change from baseline (CFB) in MRI spine and sacroiliac joint SpA Research Consortium of Canada Hier steht eine Anzeige.
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Vaginal infection in pregnant women under immunomodulatory therapy during pregnancy with systemic autoimmune inflammatory conditions. A retrospective analysis
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Histone deacetylase 1: (HDAC1): a key player of T cell-mediated arthritis
Ultrasound-verified enthesophytes are associated with radiographic progression at entheses in psoriatic arthritis
Ixekizumab significantly improves signs, symptoms and spinal inflammation of active ankylosing spondylitis/Radiographic
Abstracts infection (Candida infection, ADA arm), one case of inflammatory bowel disease (IXEQ2W arm) and no malignancies or deaths. Conclusion: The primary and all major secondary endpoints for IXE were met at Wk 16 with no unexpected safety findings. IXE was superior to PBO for improving r-axSpA signs and symptoms, with improvements in ASAS40, ASAS20 and BASDAI50, and CFB of inflammation on MRI, hs-CRP and individual ASAS components in patients with r-axSpA naïve to bDMARDs.
(SPARCC) scores (all images were centrally read). In addition, the CFB is reported for high sensitivity C-reactive protein (hs-CRP) and the 4 patient domains used for calculation of the ASAS response: patient's global assessment (PGA), BASFI, spinal pain and BASDAI stiffness. Categorical endpoints were analysed by logistic regression with non-responder imputation for missing data. Continuous endpoints were analysed by a mixedeffects model of repeated measures. Safety was assessed. Results: Of 341 subjects randomized, 97 % completed Wk 16. Baseline demographics and disease characteristics were comparable among study arms: mean age was 41.7 years; mean time since r-axSpA symptoms onset was 16.0 years, and mean BASDAI was 6.7. At Wk 16, significantly higher proportions of IXE-treated patients achieved ASAS40, ASAS20 and BASDAI50 vs PBO. Compared with PBO, both IXE regimens had significantly higher CFB improvements in MRI spinal and sacroiliac joint inflammation and hs-CRP at Wk 16 and, as early as Wk 1, significant CFB improvements in all ASAS components. At Wk 16, ADA showed significant improvements vs PBO for ASAS40 and for PGA, BASFI, NRS spinal pain and BASDAI stiffness CFB. Frequencies of treatment-emergent and serious adverse events are shown (. Tab. 1). There was one opportunistic Results are expressed as proportions of patients in the intent-to-treat population calculated using non-responder imputation. P-value for differences between ixekizumab and placebo by Chi-square tests or Fisher's exact tests Abbreviations: ACR20/50/70=20/50/70 % improvement from baseline in ACR criteria; ACR American College of Rheumatology, DAPSA Disease Activity Index for PsA, INV investigators, ITT intent-to-treat, LDA low disease activity, LDI-B Leeds dactylitis index-basic, LEI leeds enthesitis index, MDA minimal disease activity, NRI non-responder imputation, PASI psoriasis area severity index, PsA psoriatic arthritis, SJC swollen joint count, TJC tender joint count trials (5 Ph3, 3 Ph2, 1 Ph 1b) and 1 LTE (data to February 13, 2018). Placebo (PBO) comparisons were evaluated to Week 24 from 7 Ph2/3 trials: pts randomized to PBO, BARI 2-mg or 4-mg, with censoring at rescue/ treatment switch. Dose responses were evaluated in the 2-mg/4-mg extended dataset from 4 Ph2/3 trials: pts randomized to 2-mg or 4-mg, LTE data included; data censored at rescue/dose change (as-treated analysis) and analyzed without Results: Totally, 3770 pts received BARI (10,127 PYs); maximum exposure was 7 years. No significant differences were seen for BARI 4-mg vs PBO in adverse events leading to permanent drug discontinuation, death, malignancy, serious infection, or major adverse cardiovascular events. Herpes zoster IR was significantly higher for BARI 4-mg than PBO (3.8 vs 0.9) and numerically higher for BARI 2-mg (3.1). The IRs for deep vein thrombosis/pulmonary embolism were numerically higher in BARI 4-mg than PBO; IRs were similar by dose in 2-mg/4-mg extended dataset. Malignancy (excluding non-melanoma skin cancer) IRs were 0.8 (2 mg) and 1.0 (4 mg; as-randomized analysis). Fewer than 1 % pts discontinued for abnormal laboratory results. Conclusion: BARI maintained a safety profile similar to that previously reported and acceptable in the context of demonstrated efficacy.
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Goals: Baricitinib (BARI), an oral, selective inhibitor of Janus kinase (JAK)1/2, is used to treat moderate to severe rheumatoid arthritis (RA) in adults. We describe the drug's safety profile with updated data from an additional Phase (Ph) 3 trial and an on-going long-term extension (LTE) study Aim: Baricitinib (BARI), an oral, selective inhibitor of Janus kinase (JAK)1/2, is used to treat moderate to severe rheumatoid arthritis (RA) in adults. We describe the drug's safety profile with updated data from an additional Phase (Ph) 3 trial and an on-going long-term extension (LTE) study. Methods: Long-term safety of once-daily BARI was evaluated in the All-BARI-RA dataset: all patients (pts) exposed to BARI from 9 randomized All statistical comparisons were made between placebo and active treatment arms. ADA represents an active reference; the study was not powered to test equivalence or noninferiority of active treatment arms to each other, including IXE versus ADA. Intention-to-treat population: All randomized patients, analyzed according to the treatment to which they were assigned. Safety population: All randomized patients who received ≥1 dose of study treatment, analyzed according to the treatment to which they were assigned. ADA adalimumab, ASAS Assessment of Spondyloarthritis International Society criteria, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, IXEQ2W ixekizumab every 2 wks, IXEQ4W ixekizumab every 4 wks, NRS numeric rating scale, PGA patient's global assessment, SPARCC Spondyloarthritis Research Consortium of Canada Abstracts pts achieving both ACR50 and PASI100 responses at wk 24. Key secondary objectives versus ADA at wk 24 were (1) non-inferiority of IXE for ACR50 (noninferiority margin-12 %) and (2) superiority of IXE for PASI100. Additional PsA, skin, composite treat-to-target (T2T: MDA, DAPSA 4), PAS-DAS remission and patient-reported outcomes, and safety were assessed. Nine pts had PASI=0 and BSA≥3 % (a medical inconsistency) at baseline; these pts were considered PASI100 responders if PASI=0 and BSA=0 at wk 24. Categorical variables were evaluated using logistic regression analyses with NRI in the ITT population. Continuous variables were analysed using mixed models for repeated measure analysis. Results: 566 pts were randomised (283 to IXE and 283 to ADA). Baseline demographics and disease characteristics were generally well balanced between groups ( Table 1 ). All primary and key secondary efficacy endpoints at wk 24 were met ( Figure) . The proportion of pts achieving both ACR50 and PASI100 was significantly greater for IXE than ADA (36 % vs 28 %; p<0.05). IXE was non-inferior to ADA for ACR50 response and superior for PASI100 response (. Fig. 1 ). While improvements from baseline were achieved with both treatments, significantly better results were seen with IXE vs ADA for skin and composite T2T outcomes, enthesitis resolution ( Figure) , and skin-related quality of life (Table 2) . No unexpected safety signals were observed.
Conclusion:
In bDMARD naive pts with active PsA and skin disease, IXE showed superior efficacy to ADA based on simultaneous achievement of ACR50 and PASI100 responses at wk 24. Greater improvements with IXE vs ADA were also attained in individual PsA domains and composite T2T outcomes. into a 5-year progression-risk of 4 %, 10 % and 2 % in MGUS pts. without rheumatologic co-morbidity, concomitant non-Ab-mediated and Abmediated RDs, respectively. Taking the complex risk-stratification model including, M-protein concentration, Ig-type and level of FLC ratio as variables, again the pts. strata with non-Ab-mediated RDs (n=57) faced the highest risk for progression (HR= 6.8 [95 % CI 1.5-30.7], P=0.02) versus pts. with Ab-mediated RDs (n=77). Conclusion: Chronic inflammatory diseases impact the progression risk of MGUS into overt MM. However, the prognostic impact is not consistently negative, as some RDs (e.g. RA and connective tissues diseases) are even protective, whereas others clearly increase the risk of progression (e.g. gout, PMR, SpA). It remains unclear how the underlying inflammatory conditions and/or treatment of the RD impacts the progression risk. The ultimate goal is to further refine the currently applied prognostic scores in MGUS by considering autoimmune co-morbidities.
Rheumatologic diseases impact the progression risk of MGUS to overt Multiple Myeloma
N. Steiner 1 , G. Göbel 2 , D. Michaeler 3 , A. Platz 1 , W. Prokop 4 , A. M. Wolf 5 , D. Wolf 6 , C. Duftner 1 , E.
Fig. 1 8
Proportion of patients achieving primary and secondary outcomes at wk 24. Pts were stratified by conventional synthetic DMARD use and presence of moderate to severe psoriasis. a There were 189 IXE-and 171 ADA-treated pts with SPARCC enthesitis index scores >0 at baseline; these patients were evaluated at wk 24. b There were 42 IXE-and 58 ADA-treated pts with LDI scores >0 at baseline; these patients were evaluated at wk 24. ADA, adalimumab 80 mg wk 0 then 40 mg every 2 wk from wk 1 for pts with moderate to severe psoriasis or 40 mg wk 0 then 40 mg every 2 wk for pts without moderate to severe psoriasis; IXE, ixekizumab 160 mg wk 0, then 80 mg every 2 wk to wk 12 and every 4 wk thereafter for pts with moderate to severe psoriasis or 160 mg wk 0, then 80 mg every 4 wk for pts without moderate to severe psoriasis; ACR, Aim: As seen in previous analysis, the prevalence of anemia in rheumatoid arthritis (RA) patients is decreasing due to new therapeutic options from between 30 and 66% to around 21% in our cohort. In a study cohort witch was designed to evaluate iron metabolism in chronic inflammation, we further analysed the characterization of anemia in RA patients. Therefore we investigated the type of anemia in RA outpatients at our tertiary centre and evaluated the iron state in monocytes. We also looked for the impact of disease activity and therapy strategies on the prevalence and type of anemia. Methods: In the database we included patients with rheumatic diseases with or without biological treatment. Blood count, iron parameters (iron,
Abb. 1 8 Anzahl B-Linien 21 Patienten
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Tenderness is no sign of inflammation in rheumatoid arthritis, psoriatic arthritis or osteoarthritis
I. Gessl
Abtl. für Rheumatologie, Meduni Wien, Vienna, Austria
Aim: In inflammatory joint diseases, joint swelling is regarded as a sign of inflammation, which is associated with structural progression. However, the significance of tenderness without swelling is unclear. The aim of this study was to determine whether clinical tenderness can be considered a sign of inflammatory joint activity in patients with rheumatoid arthritis (RA), osteoarthritis (OA), or psoriatic arthritis (PsA) Methods: 34/26/31 patients respectively with RA, OA and PsA were included in the study. Each patient underwent clinical examination, followed by an ultrasound examination of bilateral MCP 1-5 (metacarpophalangeal), PIP 1-5 (proximal interphalangeal) joint and wrists; the sonographer was blinded to clinical data. On clinical examination synovial swelling and tenderness were evaluated using a binary scoring method, and tender, non-swollen joints (TNS) were identified. Grey-scale signs of synovitis (GS) and Power Doppler signal (PD) were evaluated using a semi- Aim: Data is limited regarding pregnancies and family planning with inflammatory rheumatic diseases. In May 2017, in the hope to collect more experience and data in this topic the nationwide Austrian Register for Reproduction and Rheumatic disease (RhePro Register) was established at the Medical University of Vienna. Methods: The RhePro Register is a prospective nationwide, web-based longitudinal observational cohort study. Pregnant patients with confirmed diagnosis of inflammatory rheumatic disease are eligible to be enrolled until the 20th week of pregnancy or patients who wish to conceive. Clinical and laboratory course of rheumatic disease, the course of pregnancy, maternal and fetal complications during and after pregnancy and information of pharmaceutical treatment throughout the pregnancy and 3 years postpartal will be documented and collected. The collected data is pseudoanonymized and data handling is conform with the data protection policy. Results: The RhePro Register started on 15th of May 2017. Until the end of January 2018, 89 patients were recruited. 36 pregnant women delivered their children, 17 women are currently pregnant and 36 women are in prae- . 1) . Patient inclusion was based on the experience of ≥1 BI before rescue and availability of a CRP measure within ± 3 days of the start of the BI. Multiple CRP measures per patient were aggregated into the median resulting in 2 observations per patient conceptional care. Of these patients 31 suffered from systemic lupus erythematosus, 11 from Sjögrens syndrome, 7 had other connective tissue diseases, 22 rheumatoid arthritis, 10 spondyloarthritis, 2 juvenile idiopathic arthritis, 2 psoriatic arthritis, and 3 systemic vasculitis. Average birthweight of the newborn was 2895 gr, average gestations week at delivery was 38 weeks. 9/36 (25 %) of the newborn were either small for gestational age (n=7 SGA) or had an intrauterine growth restriction (n=2 IUGR) and 75 % of the newborn were appropriate for gestational age (AGA) at delivery. Pregnancy complications included 1 HELLP syndrome, 6 patients experienced preterm delivery before gestational week 37, one patient had a postpartal deep venous thrombosis, 6 newborn were admitted to the neonatal intensive care unit postpartal, one child had a complex heart malformation.
Conclusion:
The Austrian RhePro Register is launched. We hope to contribute to the present knowledge of patients with inflammatory rheumatic disease and pregnancy or present family planning. Aim: Transthoracic lung ultrasound (TTLU) detects several sonographic artefacts that correlate with interstitial lung disease (ILD) in systemic sclerosis (SSC). Notably, an increase of the pleura thickness of about 2,8 mm is common in SSC. We investigated the thickness of the pleura in patients treated with rituximab and mycophenolate mofetil in comparison to patients without treatment. Methods: A TTLU was performed in 37 consecutive SSC patients to monitor the occurrence and severity of sonographic changes. TTLU was performed with a linear and an abdomen sonography probe by an experienced investigator in lung ultrasound. The following ultrasound findings were documented in each study patient: B-lines, subpleural nodes and irregularities and thickness of the pleura on 24 areas at the right and left side of the lung. Group comparisons were performed between SSC patients under immunosuppressive therapy with rituximab and mycophenolate mofetil (n=12) and without therapy (n=25 Fig. 1 ) and the maximum values were 99.2 and 25.4 mg/L, respectively. For PBO, the median CRP were 10.1 and 13.7 mg/L for the infection and infection-free period (p=0.896); and the maximum values were 110.8 and 71.4 mg/L. Conclusion: CRP remains a useful monitoring tool for BI in BARI-treated patients. CRP elevations were observed in BARI-treated patients during BI, with no apparent blunting of response. In the PBO patients, elevations of CRP also were observed in infection-free periods, in line with the presence of active RA, and these values may be comparable to the CRP values observed on those patients during a BI. corresponding to the infection and infection-free period (Figure) . Paired comparisons between CRP at infection and infection-free states were done within the same patients for each treatment group and p-values for the two differences were obtained from a Wilcoxon Signed-Rank test. . 1) . Sensitivity was 52.2% for the IgG and 30.4% for the IgA assay, respectively, resulting in high positive likelihood ratios (LR+) of 47.5 (IgG) and 50.7 (IgA). However, IgA antibodies did not show an added diagnostic value since all positive patients were also IgG positive. The anti-CCP3.1 assay was slightly more sensitive than the anti-CCP2 IgG assay (55.4%) but specificity was markedly lower and amounted to 95.9% versus healthy subjects and 90.8% versus disease controls resulting in a LR+ of only 6.0. Out of 360 disease controls 33 (9.2%) were found to be positive for CCP3.1 but among these only four (1.1%) were positive for anti-CCP2 IgG (and 2 of these also for anti-CCP2 IgA). The most common diagnosis of CCP3.1 positive control patients was osteoarthritis (12 patients); six patients suffered from spondyloarthropathies, two patients had reactive arthritis, 10 patients were diagnosed with an autoimmune rheumatic disease (AI RMD) and two patients had osteoporosis. However, at a cut-off of 60 AU/ml only nine disease controls remained positive (3 OA, 1 SpA, 4 AI RMD, 1 ReA) and 3 of them were also positive in the anti-CCP2 as-
Thickness of the pleura decreases significantly during therapy with rituximab and mycophenolate mofetil in systemic sclerosis
CRP changes during bacterial infections in baricitinib-treated patients with RA
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature review informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
Tab. 1 Head-to-head studies investigating biological DMARDs or tsDMARDs versus other biological DMARDs
Results:
Of 7876 unique abstracts 234 were selected for detailed review with 136 finally included. Twenty-one studies investigated the efficacy of bDMARDs vs. placebo, with 14 studies meeting their primary efficacy endpoint (PEP). Seven head-to-head (H2H) trials comparing bDMARDs and three H2H trials comparing tsDMARD to bDMARDs were included (. Tab. 1) . Twenty placebo-controlled trials demonstrated efficacy of JAK inhibitors across different patient populations. Two studies investigated switching of bDMARD therapy in TNFi primary non-responding patients: one trial evaluated the superiority of switching to non-TNFi bDMARDs and met its PEP, while the second evaluated superiority of switching from adalimumab to certolizumab-pegol (CZP) but did not meet its PEP. Stopping or tapering of bDMARDs and/or csDMARDs/GCs was investigated in 22 studies. Using concomitant csDMARDs when tapering bDMARDs lowered the risk of flaring, while tapering csDMARDs in patients with ongoing bDMARD therapy increased the risk of flaring in most studies. All studies investigating biosimilars (n=17) showed non-inferiority compared to their reference products. Further, switching between bDMARD originators and their respective biosimilars showed non-inferiority across all studies (n=11). An open-label strategy trial compared an MRI-guided treat-to-target (T2T) strategy to a conventional T2T strategy (using DAS28-CRP) and failed to show any benefit regarding clinical outcome or radiographic progression.
Conclusion:
The efficacy of many different bDMARDs as well as tsD-MARDs was shown in studies included in this SLR. Switching to TNFi or non-TNFi bDMARDs after TNFi treatment failure seems to be feasible. Tapering of bDMARDs as well as csDMARDs is possible in patients achieving long-standing clinical remission but may increase the risk of disease flare. Biosimilars were non-inferior to their reference products. Aim: Paradoxical inflammatory reactions including psoriasis, Crohn's disease or uveitis related to TNF-inhibitors have been described. The diagnosis often reveals to be challenging, as well as treatment strategies. Methods: We will present the case of a child with a long-term history of severe relapsing chronic non-bacterial osteomyelitis (CNO) that developed paradoxical psoriasis under treatment with adalimumab. The common therapy strategies for CNO (including methotrexate, TNF-inhibitors, bisphosphonates) did not bring significant and consistent improvement and control of disease activity. Results: The initiation of tofacitinib brought a fast improvement of the skin affection and even led to a reduction of bone inflammation.
Rheumatologische Versorgung im ländlichen Raum -das Rheumabus Projekt 2018
Conclusion:
The JAK-inhibitor Tofacitinib developed to be a therapeutic option for severe autoimmune diseases including rheumatoid arthritis and psoriasis-arthritis. To date, no JAK-inhibitor is approved for the pediatric population. In special cases, that are resistant to other therapeutic options as described above, we assume that the treatment with JAK-inhibitors could be a contemplable off-label alternative for selected patients. , n=5) gestellt, entsprechend 3,2 % aller untersuchten PatientInnen. FCP-Werte der JIA-CED-Gruppe unterschieden sich von jenen der JIA-non-CED-Gruppe in der Höhe (median[range]; say (ReA, SpA, SLE). When applying 60 AU/ml (high positive) as cut-off value at the early RA cohort, sensitivity (52.7%) became comparable to the anti-CCP2 assay and both specificity (97.5%) and LR+ (21.08) increased substantially. Conclusion: Thus, when interpreting the results of CCP assays disease specificity should be taken into account in order to reduce the risk of a false positive diagnosis.
Fäkales Calprotectin zur Detektion Chronisch entzündlicher Darmerkrankungen bei Juveniler idiopathischer Arthritis
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Anti-RA33 antibodies as diagnostic markers in early rheumatoid arthritis Aim: Anti-RA33 antibodies have been observed in rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) negative patients, and thus may provide added diagnostic value of early rheumatoid arthritis (RA). This study aimed to investigate the prevalence and diagnostic value of RA33 antibodies in patients with early RA. Methods: Sera from an investigation cohort (Vienna early RA cohort) comprising 134 early RA patients as well as a validation cohort (Leeds early RA cohort) of 131 early RA patients (both satisfying 2010 ACR/EULAR classification criteria) were tested for the presence of IgA, IgG and IgM isotypes of anti-RA33 antibodies, which were detected by newly developed prototype assays using the EliA™ platform (Thermo Fisher Scientific). The cut-off values were chosen to achieve specificities of ≥95 % against disease controls and 98 % against healthy subjects [1] . In addition, RF-IgM as well as ACPA-IgG was detected by EliA™ (Thermo Fisher Scientific). Results: In the investigation cohort anti-RA33 antibodies were detected in 15.7 % of early RA patients. The anti-RA33 IgM isotype showed the highest sensitivity (10 %) followed by IgG (6 %) and IgA (3.7 %) isotypes. Importantly, anti-RA33 antibodies were detected in 8 out of 51 seronegative patients, reducing the 'serological gap' left by RF and ACPA routine testing by 15.7 %. Interestingly, the prevalence of anti-RA33 antibodies in the validation cohort was considerably higher with 37.4 % of patients positive for at least one anti-RA33 antibody isotype. The highest sensitivity was found for the anti-RA33-IgG isotype (20.6 %) followed by IgA (16 %) and IgM (14.5 %). 12 out of 49 seronegative patients had anti-RA33 antibodies, resulting in an added diagnostic value of 24.5 %.
Conclusion:
This study suggests anti-RA33 antibody testing may aid in the diagnosis of (otherwise labelled seronegative) early RA. The wide-ranging prevalence in the tested cohorts however implies variable diagnostic power. Further investigation may clarify whether genetic and environmental factors influence anti-RA33 antibody development. Aim: The current literature on management of patients with musculoskeletal pain indicates that factors related to patient expectations and motivations are associated with both clinical outcomes, satisfaction with treatment, and influences behavior. The purpose of this study was to examine individuals' expectations and motivations with regard to their ability to predict health and well-being outcomes in a diverse sample of individuals many of which were diagnosed with rheumatological disorders and seeking treatment at the Gastein healing galleries. Methods: Patients were 1444 individuals diagnosed with ankylosing spondylitis (23%), arthritis (22%), or fibromyalgia (9%) or individuals who were undiagnosed but seeking relief of chronic pain (46%). Average age was 58 years, about 52% were female, and almost three quarters (73%) had a high school education or less. One-third was employed, just over one-third was retired (37%), and the remaining percentage held other roles (e.g., homemaker, student, disabled, etc.). Expectations were measured using 5 items and motivations were measured using 6 items. Health and well-being measures included: pain, self-rated physical health, life-satisfaction, depression, anxiety, stress, fatigue, and sleep problems. Data were analyzed using FCP1: 787 [489-1123] vs 22,5[20-764] Conclusion: A high proportion of our cohort with AS, RA and PA reported considerable improvement in their health conditions since they perform regular visits to the galleries. Over 2/3 of all patients agreed or mostly agreed that their symptoms and pain and thus their health condition improve with gallery sessions. Patients are also highly motivated to take sessions because a large proportion feel that the galleries help them to improve physical functioning, participation and preserve their ability to work. To conclude, from our patients´ point of view regular gallery sessions have important positive effects on a variety of domains including symptoms, health status, functioning and participation and help them to improve their health condition in the future. Results: Measurement models were used to first confirm that each construct was a unidimensional, well-fitting construct. Both one-and two-factor measurement models were estimated to determine if expectations and motivations scales were unique. The one-factor model did not fit the data well χ2 = 3493.64, p < 0.001. The two-factor model fit the data significantly better, χ2 = 1208.31, p < 0.001, χ2 = 2285.33, p < 0.001 suggesting that expectations and motivations are unique constructs, though they are highly related, r = 0.71, p < 0.001. Structural models revealed that both expectations and motivations were significant predictors of health and well-being, after controlling age, sex, and education. Motivations were positively related to health and well-being (Beta = 0.33, p < 0.001) while expectations were negatively related to health and well-being (Beta = −0.14, p = 0.001). Further investigation of the paradox revealed that expectations were serving as a statistical suppressor of the relationship between motivations and health and well-being. Conclusion: While weakly positively related to health and well-being at the bivariate level, the association between expectations and health and wellbeing reversed direction in the structural model and acted to increase the magnitude of the association between motivations and health and well-being. Hence, this is a classic example of net statistical suppression in which the key finding is that motivations for attending the healing galleries are an important predictor of actual health and well-being outcomes. Abstracts this work aims to explore effects and mechanisms at the cellular level. We investigated NMRT induced changes of the Methods: Human primary chondrocytes and the chondrocyte cell line Tc28/2a were used for the experiments while NMRT treatment was applied for 5 × 1 h within a time-span of two days. RNA was extracted using RNeasy Mini Kit and was used as input for the Thermo Fisher Ion Total RNA-Seq Kit v2. Sequencing was performed on Ion Proton sequencer using the Ion PI Hi-Q™ Sequencing 200 system. Signal processing and base calling was performed using Torrent Suite version 5.6. Hypoxic conditions were established and enabled cell growth in presence of 1-5 % O2. Expression of miRNAs and target proteins was studied by a standard PCR procedure as well as protein detection by western blot. Histon-Deacetylasen (HDAC) activity was measured by HDAC-Glo I/II assay. Results: Characterization of the miRNA profile showed a slight up regulation of miR-24-1-5p and miR-502-5p while miR-25-5p and miR-365a-5p was down regulated after NMR treatment. For miR-365a-5p known to directly targeting HDAC and NFkB a decrease of HDAC activity by NMRT was detected. The miR-25-5p targeting COX2 was changed in expression by NMRT whereas no influence on CDK4 was detected known to be controlled by miR-24-1-5p. NMRT treatment of chondrocytes under hypoxic conditions (1-5 % O2) changed the expression profile with respect to NOS, IGF2, PDGF and IGFBP and a change in the expression of Hif1/2 under the influence of IL1beta was observed. Concerning the hypoxic conditions modifying apoptotic behavior of the cells, NMRT showed no influence. Conclusion: Our investigations concerning the influence of the NMRT at the cellular level revealed a modulatory effect on miRNA, their regulatory units and chondrocytes under hypoxic conditions. The results underline our former findings indicating that NMRT counteracts IL-1b induced changes. Therefore we deduce that pain reduction by NMRT might be due to NMRT holding against inflammatory mechanisms under OA. Aim: Osteoarthritis (OA) is the most common joint disease characterized by progressive degradation of articular cartilage, synovial hyperplasia, bone remodeling and angiogenesis. As the main consequences, patients suffer from loss of function and joint pain, followed by psychological distress and significant restrictions in daily living. While OA induced pain represents the most frequent cause of chronic pain, its mechanisms are poorly understood and treatments are not satisfactory. The development of more effective and in particular non-invasive methods to gain pain reduction of OA patients therefore is of exceptional interest. Clinical trials based on therapeutically applied nuclear magnetic resonance (NMRT) embedded within the treatment of patients with degenerative rheumatic diseases revealed pain reduction as the main clinical outcome. Improvements in pain of patients with low back pain or knee OA have been documented, the latter being explained by chondroprotective effects on the articular cartilage induced by NMRT. It is in addition noteworthy to mention that the observed reduction in pain sustained for up to one year. While NMRT is discussed to participate in repair processes regarding cartilage and may influence pain signaling, the mechanisms of action of NMRT at the cellular level remain to be illuminated. To substantiate the application of NMRT 
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